The Impact of Clinical Prognosis of Viral Hepatitis in Head and Neck Cancer Patients Receiving Concurrent Chemoradiotherapy

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Nov 25

PMID 38001947

Authors

Yu-Ming Wang

Sheng-Dean Luo

Ching-Nung Wu

Shao-Chun Wu

Wei-Chih Chen

Yao-Hsu Yang

Tai-Jan Chiu

Affiliations

Soon will be listed here.

Abstract

This study evaluated the clinical characteristics of head and neck cancer (HNC) patients with hepatitis B (HBV) or hepatitis C (HCV) who underwent concurrent chemoradiotherapy (CCRT) and examined the prognostic impact of antiviral therapies. In a 19-year retrospective analysis of 8224 HNC patients treated with CCRT, 29.8% (2452) were diagnosed with HBV or HCV, of whom 714 received antiviral therapy. For non-metastatic HNC patients on CCRT, factors such as gender, Charlson Comorbidity Index (CCI), liver cirrhosis markers (Fibrosis-4, APRI), and initial tumor stage were significant determinants of their overall survival. However, the presence of HBV or HCV and the administration of antiviral treatments did not yield distinct survival outcomes. In summary, antiviral therapy for HBV or HCV did not affect the 5-year survival rates of non-metastatic HNC patients undergoing CCRT, while gender, tumor stage, CCI, and liver cirrhosis were notable prognostic indicators.

References

Lok A, McMahon B . Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3):661-2. DOI: 10.1002/hep.23190. View

Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W . Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016; 1(2):e000042. PMC: 5070280. DOI: 10.1136/esmoopen-2016-000042. View

Chow L . Head and Neck Cancer. N Engl J Med. 2020; 382(1):60-72. DOI: 10.1056/NEJMra1715715. View

Xie L, Shang Z . Burden of oral cancer in Asia from 1990 to 2019: Estimates from the Global Burden of Disease 2019 study. PLoS One. 2022; 17(3):e0265950. PMC: 8947401. DOI: 10.1371/journal.pone.0265950. View

Torres H, Hosry J, Mahale P, Economides M, Jiang Y, Lok A . Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study. Hepatology. 2017; 67(1):36-47. PMC: 5739995. DOI: 10.1002/hep.29344. View

. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2008; 50(2):227-42. DOI: 10.1016/j.jhep.2008.10.001. View

Hwang J, Somerfield M, Alston-Johnson D, Cryer D, Feld J, Kramer B . Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Clin Oncol. 2015; 33(19):2212-20. PMC: 4477791. DOI: 10.1200/JCO.2015.61.3745. View

Ganem D, Prince A . Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004; 350(11):1118-29. DOI: 10.1056/NEJMra031087. View

Boje C, Dalton S, Primdahl H, Kristensen C, Andersen E, Johansen J . Evaluation of comorbidity in 9388 head and neck cancer patients: a national cohort study from the DAHANCA database. Radiother Oncol. 2014; 110(1):91-7. DOI: 10.1016/j.radonc.2013.11.009. View

10.

Li Y, Chen W, Tsai W, Cheng J, Tsay F, Kao S . Severe acute exacerbation of HCV infection in cancer patients who undergo chemotherapy without antiviral prophylaxis. J Viral Hepat. 2020; 27(9):873-879. DOI: 10.1111/jvh.13302. View

11.

Sindhu S, Bauman J . Current Concepts in Chemotherapy for Head and Neck Cancer. Oral Maxillofac Surg Clin North Am. 2018; 31(1):145-154. PMC: 6524526. DOI: 10.1016/j.coms.2018.09.003. View

12.

Shih C, Chen W, Yu H, Cheng J, Lai K, Hsu J . Risk of Severe Acute Exacerbation of Chronic HBV Infection Cancer Patients Who Underwent Chemotherapy and Did Not Receive Anti-Viral Prophylaxis. PLoS One. 2015; 10(8):e0132426. PMC: 4537229. DOI: 10.1371/journal.pone.0132426. View

13.

Liu C, Chiu T, Huang T, Chien C, Fang F . Impact of comorbidity on survival for locally advanced head and neck cancer patients treated by radiotherapy or radiotherapy plus chemotherapy. Chang Gung Med J. 2010; 33(3):283-91. View

14.

Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V . FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007; 46(1):32-6. DOI: 10.1002/hep.21669. View

15.

Torres H, Davila M . Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012; 9(3):156-66. DOI: 10.1038/nrclinonc.2012.1. View

16.

Weng J, Wei J, Li M, Lu J, Qin Y, Jiang H . Effects of hepatitis B virus infection and antiviral therapy on the clinical prognosis of nasopharyngeal carcinoma. Cancer Med. 2019; 9(2):541-551. PMC: 6970022. DOI: 10.1002/cam4.2715. View

17.

Zhang Y, Wang R, Yang X . FIB-4 index serves as a noninvasive prognostic biomarker in patients with hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore). 2018; 97(51):e13696. PMC: 6320186. DOI: 10.1097/MD.0000000000013696. View

18.

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

19.

Nobles J, Wold C, Fazekas-May M, Gilbert J, Friedlander P . Prevalence and epidemiology of hepatitis C virus in patients with squamous cell carcinoma of the head and neck. Laryngoscope. 2004; 114(12):2119-22. DOI: 10.1097/01.mlg.0000149444.30017.e8. View

20.

Zhang C, Wu J, Xu J, Xu J, Xian J, Xue S . Association between Aspartate Aminotransferase-to-Platelet Ratio Index and Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis: A Meta-Analysis of Cohort Study. Dis Markers. 2019; 2019:2046825. PMC: 6877976. DOI: 10.1155/2019/2046825. View